Clark Eliana 4
4 · Intellia Therapeutics, Inc. · Filed Jan 5, 2024
Insider Transaction Report
Form 4
Clark Eliana
EVP, Chief Technical Officer
Transactions
- Sale
Common Stock
2024-01-03$29.46/sh−4,301$126,707→ 40,845 total - Sale
Common Stock
2024-01-03$30.12/sh−307$9,247→ 45,146 total
Footnotes (2)
- [F1]Sale of 307 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2023.
- [F2]Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person.